A simple test can predict whether smokers will manage to quit
en-GBde-DEes-ESfr-FR

A simple test can predict whether smokers will manage to quit


Data from nearly 6000 smokers with cancer show that it may be easier to predict who will stop smoking than was previously thought.

It is often important to get cancer patients to quit smoking, but it is not always that easy.

“Data suggest that between 15 and 60 per cent of people who smoked before they were diagnosed with cancer continue to smoke after their diagnosis. It is crucial to help people with cancer quit smoking, because it will lead to better cancer treatment prognoses, prevent secondary cancer, and increase quality of life,” says Rubén Rodríguez-Cano, an associate professor at the Norwegian University of Science and Technology (NTNU) Department of Psychology.

Degree of addiction

Because smoking and cancer often go hand-in-hand, it is especially useful to determine how addicted people are to smoking. That makes it possible to estimate how likely it is that people will manage to quit, and consequently predict cancer patients’ chances of surviving.

The researchers may also be able to use a similar approach to estimate the risk that smokers who are still healthy have of developing cancer at a later date.

“We are currently conducting another study on the risk of developing lung cancer, which is being led by Professor Oluf Dimitri Røe. Among the variables are nicotine addiction, smoking history and BMI,” says Rodríguez-Cano.

However, investigating smoking addiction requires considerable resources. Therefore, Rodríguez-Cano wanted to find out whether there is a more efficient way of measuring the degree of a smoker's addiction.

He collaborated with people from one of the foremost cancer hospitals in the world, the University of Texas MD Anderson Cancer Center in Houston, Texas.

Long and short tests

Several tests can be used to ascertain smoking addiction. The gold standard is the Fagerström Test for Cigarette Dependence (FTCD).

“But this test is too extensive when we want to check a large number of patients to assess smoking risk at group level,” says Rodríguez-Cano.

So, is a longer test really necessary? A simplified version called the Heaviness of Smoking Index (HSI) comprises only two questions:

  • How many cigarettes do you smoke per day?
  • How soon after you wake up do you smoke your first cigarette?

And these two questions are sufficient. Try it yourself.

A simplified test is often sufficient

“We investigated nearly 6000 cancer patients to see if it made any difference whether they took the full test or the simplified one,” says Rodríguez-Cano.

It generally did not make a difference.

“The results in predicting cigarette addiction were equally good for both the full and the simplified tests.

In addition, the simplified test is just as good at predicting the smoking abstinence at 3, 6, and 9 months after quitting smoking following specialised treatment,” says Rodríguez-Cano. However, it is not that straight forward.

...but not for all smokers

For some reason, the simplified test does not work as well for everyone.

“The effectiveness of the simplified test for men and women depends on the patient’s race,” Rodríguez-Cano explains.

Basically, the shortest test did not work as well for Non-Hispanic Black people with a cancer diagnosis. The researchers do not know whether this is due to social or genetic factors – or a combination of both.

“Both the full test and the simplified test are useful tools, but our research shows that it may be necessary to tailor the tests for different groups,” says Rodríguez-Cano.

Nevertheless, the research may make it easier to investigate smoking addiction than before. This can reduce the burden on the healthcare system as well as on cancer patient treatment.

Rubén Rodríguez-Cano, George Kypriotakis, Jason D Robinson, Maher Karam-Hage, Janice A Blalock, Jennifer A Minnix, Diane Beneventi, Paul M Cinciripini, Comparing the Fagerström Test and Heaviness of Smoking Index in Predicting Smoking Abstinence in Cancer Patients, Nicotine & Tobacco Research, 2024; ntae120, https://doi.org/10.1093/ntr/ntae120
Regions: Europe, Norway
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement